ASCO, page-18

These are the types of questions I would love answers too......sure sometimes it is not possible for answers to be offered: These would be just some questions that quickly come to hand.

1. Has the Company considered an FDA approach for early GBM approval ?

2. To avoid the fundraising and dilution, why did the company not enter a deal (given strong Phase 2 results) . What exactly are pre GBM AGILE costs ?

3. Exactly what is the blue sky the company refer too - how is that being progressed.

4. Post Dana Farber and ALLIANCE Clinical Trial - would the company approach the FDA for early Brain metastases approvals.

5. Why not seek an Asian partner. (Background separate Asian studies required before Asian use of drugs.

6. Are their restrictions in open deal dealing, associated with the original Genentech license.